.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A08A_AntiobesityPreparationsExclDietProducts.A08AA02_Fenfluramine.Fenfluramine .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A08A_AntiobesityPreparationsExclDietProducts.A08AA02_Fenfluramine.Fenfluramine| name: | Fenfluramine |
| ATC code: | A08AA02 | route: | oral |
| n-compartments | 1 |
Fenfluramine is an amphetamine derivative previously used as an appetite suppressant for the treatment of obesity. It acts as a serotonin-releasing agent. Due to its association with pulmonary hypertension and heart valve disease, fenfluramine was withdrawn from the market in most countries in the late 1990s. It has been re-approved in some regions for the treatment of Dravet syndrome, a rare form of epilepsy, under the branded name Fintepla.
Pharmacokinetic parameters estimated for healthy adult volunteers after oral administration; typical therapeutic dose.
Mittur, A, et al., & Boyd, B (2024). Effect of Hepatic Impairment on the Pharmacokinetics of Fenfluramine and Norfenfluramine. Journal of clinical pharmacology 64(7) 887–898. DOI:10.1002/jcph.2431 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38523492
Imbeault, P, et al., & Tremblay, A (2002). Increase in plasma pollutant levels in response to weight loss is associated with the reduction of fasting insulin levels in men but not in women. Metabolism: clinical and experimental 51(4) 482–486. DOI:10.1053/meta.2002.31338 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11912558